Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer

LUO Hongmei; ZOU Jiafeng; ZHAO Jiufeng; SUN Chengxin; YANG Jianwen

doi:10.6039/j.issn.1001-0408.2024.23.14

您当前的位置：

首页 >

文章列表页 >

Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer

更新时间：2025-09-25

- Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 23, Pages: 2923-2928(2024)
- 作者机构：
  
  1.遵义医科大学附属医院药剂科，贵州遵义　563000
  2.遵义医科大学药学院，贵州遵义　563000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.23.14
  CLC： R979.1;R734.2
- Received：22 July 2024，
  
  Revised：2024-08-21，
  
  Accepted：31 October 2024，
  
  Published：15 December 2024
- 稿件说明：
移动端阅览
罗红梅,邹佳凤,赵久凤,等.PD-1/PD-L1抑制剂联合贝伐珠单抗治疗晚期非小细胞肺癌疗效与安全性的Meta分析[J].中国药房,2024,35(23):2923-2928.

LUO Hongmei,ZOU Jiafeng,ZHAO Jiufeng,et al.Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer[J].ZHONGGUO YAOFANG,2024,35(23):2923-2928.
罗红梅,邹佳凤,赵久凤,等.PD-1/PD-L1抑制剂联合贝伐珠单抗治疗晚期非小细胞肺癌疗效与安全性的Meta分析[J].中国药房,2024,35(23):2923-2928. DOI： 10.6039/j.issn.1001-0408.2024.23.14.

LUO Hongmei,ZOU Jiafeng,ZHAO Jiufeng,et al.Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer[J].ZHONGGUO YAOFANG,2024,35(23):2923-2928. DOI： 10.6039/j.issn.1001-0408.2024.23.14.

摘要

目的

评价在含铂双药治疗基础上联合程序性死亡受体1/程序性死亡受体配体1（PD-1/PD-L1）抑制剂和贝伐珠单抗治疗晚期非小细胞肺癌的疗效与安全性。

方法

检索中国知网、万方、维普、Web of Science、PubMed等中英文数据库，检索时间为建库至2024年4月25日。收集含铂双药联合PD-1/PD-L1抑制剂及贝伐珠单抗（试验组）对比含铂双药联合或不联合PD-1/PD-L1抑制剂或贝伐珠单抗（对照组）治疗晚期非小细胞肺癌的队列研究或随机对照试验。筛选文献、提取数据并进行文献质量评价后，采用RevMan 5.4.1软件进行Meta分析和敏感性分析。

结果

共纳入15篇文献，涉及13项研究，共计3 282例患者。与对照组比较，试验组有更高的部分缓解率[RR＝0.75，95%CI（0.68，0.82），

＜0.000 01

]

、完全缓解率[RR＝0.47，95%CI（0.29，0.76），

＝0.002

]

、疾病进展率[RR＝1.23，95%CI（1.11，1.3

7），

＜0.000 1

]

、客观缓解率[RR＝0.72，95%CI（0.67，0.79），

＜0.000 01

]

和疾病控制率[RR＝0.85，95%CI （0.77，0.95），

＝0.003

]

，两组患者的疾病稳定率[RR＝1.25，95%CI（0.86，1.83），

＝0.25

]

和总体不良反应发生率[RR＝0.95，95%CI（0.90，1.00），

＝0.07

]

差异均无统计学意义。敏感性分析表明，所有结局指标的分析结果均稳健可靠。

结论

在含铂双药治疗基础上，PD-1/PD-L1抑制剂联合贝伐珠单抗治疗晚期非小细胞肺癌具有提高患者客观缓解率和疾病控制率等临床获益，且不增加不良反应发生风险。

Abstract

OBJECTIVE

To evaluate the efficacy and safety of programmed death-1/programmed death-ligand 1 （PD-1/PD-L1） inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer （NSCLC） based on platinum-containing dual therapy.

METHODS

Retrieved from CNKI， Wanfang， VIP， Web of Science， PubMed and other Chinese and English databases， cohort studies or randomized controlled trial studies on the treatment of advanced NSCLC with platinum-containing double agents in combination with PD-1/PD-L1 inhibitors and bevacizumab （trial group） versus platinum-containing double agents with or without PD-1/PD-L1 inhibitor or bevacizumab （control group） were collected from the inception to April 25， 2024. After screening literature， extracting data and evaluating quality， meta-analysis and sensitivity analysis were performed by using RevMan 5.4.1 software.

RESULTS

A total of 15 pieces of literature were included， involving 13 clinical studies with a total of 3 282 patients. Compared with the control group， partial response rate [RR＝0.75，95%CI（0.68，0.82），

＜0.000 01

]

， complete response rate [RR＝0.47，95%CI（0.29，0.76），

＝0.002

]

， progressive disease rate [RR＝1.23，95%CI（1.11，1.37），

＜0.000 1

]

， objective response rate （ORR） [RR＝0.72，95%CI（0.67，0.79），

＜0.000 01

]

and disease control rate （DCR） [RR＝0.85， 95%CI （0.77，0.95），

＝0.003

]

were higher in the trial group. There w

as no statistically significant difference in the stable disease rate [RR＝1.25， 95%CI （0.86， 1.83），

＝0.25

]

or overall adverse drug reaction incidence rate [RR＝0.95， 95%CI （0.90， 1.00），

＝0.07

]

between the two groups of patients. Sensitivity analyses showed robust and reliable results for all outcome indicators.

CONCLUSIONS

PD-1/PD-L1 inhibitors combined with bevacizumab based on platinum-containing dual therapy in the treatment of advanced NSCLC can improve patients’ clinical benefits， such as ORR and DCR， without increasing the risk of adverse drug reaction.

关键词

Keywords

references

国家卫生健康委员会 . 原发性肺癌诊疗指南：2022年版 [J ] . 中国合理用药探索， 2022 ， 19 （ 9 ）： 1 - 28 .

National Health Commission . Guidelines for the diagnosis and treatment of primary lung cancer：2022 edition [J ] . Chin J Ration Drug Use ， 2022 ， 19 （ 9 ）： 1 - 28 .

ZHONG R ， CAI X Y ， LI J F ， et al . Asian，regional，and national burdens of respiratory tract cancers and associated risk factors from 1990 to 2019：a systematic analysis for the global burden of disease study 2019 [J ] . Chin Med J Pulm Crit Care Med ， 2023 ， 1 （ 4 ）： 249 - 258 .

LI S ， YU Z S ， LIU H Z ， et al . Immunotherapy combined with antiangiogenic therapy as third- or further-line therapy for stage Ⅳ non-small cell lung cancer patients with ECOG performance status 2：a retrospective study [J ] . Cancer Med ， 2024 ， 13 （ 11 ）： e7349 .

周娟，苏春霞 . 2023年ASCO非小细胞肺癌靶向和免疫治疗进展 [J ] . 实用肿瘤杂志， 2023 ， 38 （ 4 ）： 305 - 311 .

ZHOU J ， SU C X . Research progress on targeted therapy and immunotherapy of non-small-cell lung cancer at 2023 ASCO annual meeting [J ] . J Pract Oncol ， 2023 ， 38 （ 4 ）： 305 - 311 .

ZENG X H ， JIA Y X ， CHEN H M ， et al . A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma [J ] . J Cancer Res Clin Oncol ， 2023 ， 149 （ 11 ）： 9213 - 9219 .

SOCINSKI M A ， JOTTE R M ， CAPPUZZO F ， et al . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC [J ] . N Engl J Med ， 2018 ， 378 （ 24 ）： 2288 - 2301 .

GADGEEL S M ， STEVENSON J P ， LANGER C J ， et al . Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer：phase 1 cohorts from the KEYNOTE-021 study [J ] . Lung Cancer ， 2018 ， 125 ： 273 - 281 .

RECK M ， JOTTE R ， MOK T S K ， et al . IMpower150：an exploratory analysis of efficacy outcomes in patients with EGFR mutations [J ] . Ann Oncol ， 2019 ， 30 ： ii48 - ii49 .

BYLICKI O ， CLARISSE B ， GRELLARD J M ， et al . 1411TiP GFPC 06-2018：a multicenter non-randomized phase Ⅱ study evaluating platinum-pemetrexed-atezoli- zumab（+/-bevacizumab） for patients with stage ⅢB/Ⅳ non-squamous non-small cell lung cancer with EGFR mutations，ALK rearrangement or ROS1 fusion progressing after targeted therapies [J ] . Ann Oncol ， 2020 ， 31 ： S892 .

LEE J S ， SUGAWARA S ， KANG J H ， et al . LBA54 randomized phase Ⅲ trial of nivolumab in combination with carboplatin，paclitaxel，and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC [J ] . Ann Oncol ， 2020 ， 31 ： S1184 - S1185 .

RECK M ， WEHLER T ， ORLANDI F ， et al . Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer [J ] . J Clin Oncol ， 2020 ， 38 （ 22 ）： 2530 - 2542 .

SOCINSKI M A ， NISHIO M ， JOTTE R M ， et al . IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC [J ] . J Thorac Oncol ， 2021 ， 16 （ 11 ）： 1909 - 1924 .

黄普超，张桂芳 . 信迪利单抗联合贝伐珠单抗治疗晚期肺腺癌有效率及安全性临床观察 [J ] . 中国药物评价， 2022 ， 39 （ 1 ）： 79 - 82 .

HUANG P C ， ZHANG G F . Sindilizumab combined with bevacizumab in treatment of advanced lung adenocarcinoma [J ] . Chin J Drug Eval ， 2022 ， 39 （ 1 ）： 79 - 82 .

PARK S ， KIM T M ， HAN J Y ， et al . Phase Ⅲ，randomi- zed study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer（ATTLAS，KCSG-LU19-04） [J ] . J Clin Oncol ， 2024 ， 42 （ 11 ）： 1241 - 1251 .

SHIRAISHI Y ， KISHIMOTO J ， SUGAWARA S ， et al . Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer：a phase 3 randomized clinical trial [J ] . JAMA Oncol ， 2024 ， 10 （ 3 ）： 315 - 324 .

耿亭亭，张亚 . 帕博利珠单抗联合标准化疗加贝伐珠单抗治疗晚期非鳞非小细胞肺癌的效果 [J ] . 中外医药研究， 2023 ， 2 （ 13 ）： 22 - 24 .

GENG T T ， ZHANG Y . The efficacy of pembrolizumab combined with standard chemotherapy and bevacizumab in the treatment of advanced non-small cell lung cancer [J ] . Chin Foreign Med Pharm Res ， 2023 ， 2 （ 13 ）： 22 - 24 .

刘萍，林锦培，吕旭桦，等 . 信迪利单抗、贝伐珠单抗联合含铂双药化疗治疗EGFR-TKI耐药NSCLC患者的疗效及安全性 [J ] . 江苏医药， 2023 ， 49 （ 10 ）： 1040 - 1043 .

LIU P ， LIN J P ， LYU X H ， et al . The efficacy and safety of combination therapy with platinum based dual agent chemotherapy using sintilimab and bevacizumab for EGFR-TKI resistant NSCLC patients [J ] . Jiangsu Med J ， 2023 ， 49 （ 10 ）： 1040 - 1043 .

王鹏，郝朋朋，李全奎 . 一线PD-1单抗与贝伐单抗双靶联合化疗治疗晚期非鳞非小细胞肺癌临床观察 [J ] . 社区医学杂志， 2023 ， 21 （ 20 ）： 1052 - 1057 .

WANG P ， HAO P P ， LI Q K . Clinical observation of PD-1 immunotherapy combined with the bevacizumab and the chemotherapy for the advanced non-squamous non-small cell lung cancer [J ] . J Community Med ， 2023 ， 21 （ 20 ）： 1052 - 1057 .

郑荣香 . 信迪利单抗联合贝伐珠单抗及化疗治疗晚期肺腺癌的临床价值分析 [J ] . 北方药学， 2023 ， 20 （ 5 ）： 115 - 117 .

ZHENG R X . Clinical value of sintilimab combined with bevacizumab and chemotherapy in the treatment of advanced lung adenocarcinoma [J ] . J North Pharm ， 2023 ， 20 （ 5 ）： 115 - 117 .

HUANG Y ， YANG Y P ， ZHAO Y Y ， et al . QL1706（anti-PD-1 IgG4/CTLA-4 antibody） plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer：a multi-cohort，phase Ⅱ study [J ] . Signal Transduct Target Ther ， 2024 ， 9 （ 1 ）： 23 .

BENDELL J C ， POWDERLY J D ， LIEU C H ， et al . Safety and efficacy of MPDL3280A （anti-PDL1） in combination with bevacizumab （bev） and/or FOLFOX in patients （pts） with metastatic colorectal cancer（mCRC） [J ] . J Clin Oncol ， 2015 ， 33 （ Suppl. 3 ）： 704 .

WANG Y H ， SHI X H ， QI Q H ， et al . Safety of anlotinib capsules combined with PD-1 inhibitor camrelizumab in the third-line treatment of advanced non-small-cell lung cancer and their effect on serum tumor markers [J ] . J Healthc Eng ， 2021 ， 2021 ： 2338800 .

LIU Y X ， ZHANG T M ， ZHANG L N ， et al . Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8 + T cells in lung cancer [J ] . Immunotherapy ， 2022 ， 14 （ 9 ）： 695 - 708 .

许子宜 . 非小细胞肺癌治疗模式探索及转化研究 [D ] . 北京：中国医学科学院， 2023 .

XU Z Y . Exploration and transformation of treatment model for non-small cell lung cancer [D ] . Beijing ： Chinese Academy of Medical Sciences ， 2023 .

Views

203

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Clinical observation of vonoprazan-based triple therapy in treatment-naive patients with Helicobacter pylori infection

Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention

Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia

Related Author

WANG Wanwan

YE Jun

CHENG Hai

YAO Wei

LIU Guiling

ZHENG Jishan

CHEN Yanyan

LI Shanshan

Related Institution

Dept. of Hematology， the Third People’s Hospital of Bengbu

Dept. of Hematology， the Affiliated Hospital of Xuzhou Medical University

Dept. of Pharmacy， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Paediatrics， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Pharmacy， the University of Hong Kong-Shenzhen Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰